The Shenqi compound can effectively regulate the disorder of CD4+T lymphocyte subsets in the peripheral blood of patients with HF, increase the levels of Th17, Th17/Treg and the serum IL-10, and reduce the expression of IL-2, IL-6, IL-17, TNF-α, and IFN-γ pro-inflammatory factors. Here, CD4 is linked to hydrops fetalis.